Mast Cell Activation Syndrome (MCAS) is a silent and growing health crisis in the UK, leaving thousands without access to essential care. The immune condition can cause life-threatening anaphylaxis and debilitating, chronic symptoms, yet it remains critically underserved within the NHS.

MCAS occurs when mast cells—a type of white blood cell found throughout the body—become dysregulated and release excessive chemical mediators. This triggers chronic, repetitive allergic and inflammatory responses that can affect multiple organ systems, including the gastrointestinal tract, skin, cardiovascular system, and nervous system. Symptoms are often unpredictable and severe, with a high risk of anaphylaxis, and triggers vary widely among individuals. Common triggers include certain foods, medications, hormonal changes, stress, environmental factors, and infections.

Despite the condition carrying an significantly increased risk of life-threatening anaphylaxis—and its rising prevalence, particularly in the wake of COVID-19—MCAS continues to lack formal clinical recognition and treatment pathways within the NHS.

The National Institute for Health and Care Excellence (NICE) has yet to establish guidelines for the condition, leaving frontline NHS providers without the tools or protocols to manage this condition effectively. This has led to long referral delays, misdiagnoses, worsening patient outcomes, and a widespread lack of coordinated care.

Access to some medications for MCAS may require specialist approval and guidance. Due to a significant shortage of available NHS specialists, patients frequently encounter delays or barriers to necessary medications, including emergency medications such as epinephrine auto-injectors.

Consequently, many are forced to rely on general practitioners who, despite their best efforts, are not often not equipped to deal or treat patients with MCAS. This situation often leaves patients with no choice but to seek costly private care, where the majority of knowledgeable specialists for the condition currently practise.

In contrast, countries like the United States, Germany, France, and Australia have implemented clear guidelines, diagnostic criteria, and access to treatment for MCAS patients, while the UK is falling behind.

We are calling on NICE and NHS leadership to take urgent action by:

• Establishing formal diagnostic and treatment guidelines for MCAS
  
  
• Providing access to NHS immunologists and other relevant specialists
  
  
• Improving emergency care protocols across A&E and general practice
  
  
• Ensuring access to essential and emergency medications
  
  
• Integrating current research and evidence-based practice into NHS training and care delivery
  
  

We are asking NICE to acknowledge the urgency of this issue and to take decisive steps toward safe, consistent, and accessible NHS care for people living with MCAS.

Immediate action is crucial to improving patient outcomes, reducing preventable hospital visits, and ensuring that individuals living with MCAS receive the necessary and essential medical care they require.
Inaction puts lives at risk.